- Exchange: NASDAQ GS
- Sector: Consumer, Non-cyclical
- Industry: Commercial Services
- Sub-Industry: Research&Development
Albany Molecular Research Inc
+ Add to WatchlistAMRI:US
11.1500 USD 0.1000 0.90%As of 20:10:00 ET on 05/24/2013.
Snapshot for Albany Molecular Research Inc (AMRI)
| Open: | 11.0300 | Day's Range: | 10.8072 - 11.2200 | Volume: | 163,955 |
|---|---|---|---|---|---|
| Previous Close: | 11.1500 | 52wk Range: | 2.2500 - 12.5000 | 1-Yr Rtn: | +311.44% |
Key Statistics for AMRI
| Current P/E Ratio (ttm) | 24.2391 |
|---|---|
| Estimated P/E(12/2013) | - |
| Relative P/E vs. SPX | 1.5047 |
| Earnings Per Share (ttm) | 0.4600 |
| Est. EPS (12/2013) | - |
| Est. PEG Ratio | - |
| Market Cap (M USD) | 350.31 |
| Shares Outstanding (M) | 31.42 |
| 30 Day Average Volume | 543,505 |
| Price/Book (mrq) | 1.6403 |
| Price/Sale (ttm) | 1.4150 |
| Dividend Indicated Gross Yield | -% |
| Cash Dividend | - |
| Last Dividend | |
| 5 Year Dividend Growth | - |
| Next Earnings Announcement | 08/01/2013 |
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Income Statement for AMRI
Company Profile & Key Executives for AMRI
Albany Molecular Research, Inc., an integrated chemistry outsourcing company, offers a variety of chemistry research and development services. The Company provides its services to pharmaceutical and biotechnology companies involved in drug discovery and development. Albany offers medicinal chemistry, chemical development, analytical chemistry services, and small-scale manufacturing.
| Thomas E D'AmbraChairman/President/CEO | Bruce J SargentSenior VP:Drug Discovery |
| Steven R HagenSenior VP:Pharmaceutical Dev | Michael M Nolan "Mike"VP/CFO/Treasurer |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Financial Commentaries
Advertisement
Top Forex Trading Resources
-
AMRI News
-
Industry News
Advertisement
Advertisement
Sponsored Links
Advertisements
Rate this Page